Abstract
Objective: To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox®), and percutaneous tibial nerve stimulation (PTNS). Materials and methods: A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best–worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to −1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey’s multiple comparisons test. Results: The study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1619-1627 |
| Number of pages | 9 |
| Journal | International Urology and Nephrology |
| Volume | 47 |
| Issue number | 10 |
| DOIs | |
| State | Published - Sep 7 2015 |
Fingerprint
Keywords
- Botox
- Onabotulinum toxin A
- Patient preferences
- Percutaneous tibial nerve stimulation
- Refractory OAB treatment
- Sacral neuromodulation
ASJC Scopus subject areas
- Nephrology
- Urology
Cite this
Patient preferences for treating refractory overactive bladder in the UK. / Hashim, Hashim; Beusterien, Kathleen; Bridges, John F P; Amos, Kaitlan; Cardozo, Linda.
In: International Urology and Nephrology, Vol. 47, No. 10, 07.09.2015, p. 1619-1627.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Patient preferences for treating refractory overactive bladder in the UK
AU - Hashim, Hashim
AU - Beusterien, Kathleen
AU - Bridges, John F P
AU - Amos, Kaitlan
AU - Cardozo, Linda
PY - 2015/9/7
Y1 - 2015/9/7
N2 - Objective: To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox®), and percutaneous tibial nerve stimulation (PTNS). Materials and methods: A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best–worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to −1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey’s multiple comparisons test. Results: The study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score
AB - Objective: To evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox®), and percutaneous tibial nerve stimulation (PTNS). Materials and methods: A cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best–worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to −1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey’s multiple comparisons test. Results: The study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score
KW - Botox
KW - Onabotulinum toxin A
KW - Patient preferences
KW - Percutaneous tibial nerve stimulation
KW - Refractory OAB treatment
KW - Sacral neuromodulation
UR - http://www.scopus.com/inward/record.url?scp=84944150967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944150967&partnerID=8YFLogxK
U2 - 10.1007/s11255-015-1100-3
DO - 10.1007/s11255-015-1100-3
M3 - Article
C2 - 26347077
AN - SCOPUS:84944150967
VL - 47
SP - 1619
EP - 1627
JO - International Urology and Nephrology
JF - International Urology and Nephrology
SN - 0301-1623
IS - 10
ER -